anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Oxygen (O2) is required for aerobic energy metabolism but can produce reactive oxygen species (ROS), which are a wide variety of oxidant molecules with a range of biological functions from causing cell damage (oxidative distress) to cell signalling (oxidative eustress). The balance between the rate and amount of ROS generated and the capacity for scavenging systems to remove them is affected by several biological and environmental factors, including oxygen availability. Ectotherms, and in particular hypoxia-tolerant ectotherms, are hypothesized to avoid oxidative damage caused by hypoxia, although it is unclear whether this translates to an increase in ecological fitness. In this Review, we highlight the differences between oxidative distress and eustress, the current mechanistic understanding of the two and how they may affect ectothermic physiology. We discuss the evidence of occurrence of oxidative damage with hypoxia in ectotherms, and that ectotherms may avoid oxidative damage through (1) high levels of antioxidant and scavenging systems and/or (2) low(ering) levels of ROS generation. We argue that the disagreements in the literature as to how hypoxia affects antioxidant enzyme activity and the variable metabolism of ectotherms makes the latter strategy more amenable to ectotherm physiology. Finally, we argue that observed changes in ROS production and oxidative status with hypoxia may be a signalling mechanism and an adaptive strategy for ectotherms encountering hypoxia.
The cause of cervical cancer is a persistent infection with high-risk types of human papillomavirus (HPV). Cytology has been the gold standard for cervical screening since the introduction of routine screening with the Pap test in the 1950s due to its effect on mortality in regions with screening programs. Since that time, there have been several technological advances (LBC, Imaging) to improve and automate cervical cytology, resulting in increased disease detection and efficiency. The Hologic's Genius Digital Diagnostics System is a CE-IVD (CE-marked in vitro diagnostic device) marked digital cytology platform. For quality assurance and to prospectively evaluate the Hologic Genius Digital Cytology (DC) system in the lab, selected routinely screened and already archived slides will be additionally reviewed with the liquid-based cytology (LBC) manual microscopic approach. Only anonymized results will be evaluated.
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and ultimately fatal interstitial lung disease. With worsened dyspnea and an increasing loss of pulmonary function, IPF patients will have very poor quality of life. It has also brought an increasing social-economic burden. Researches show that pirfenidone and nintedanib could be effective to IPF, which were also recommended by the guideline. However, the application has been limited by side effects and high prices. It is urgent to develop other effective treatments and strategies to manage IPF. The investigators' previous studies shown that Jin-shui Huan-xian granule could be effective to IPF.

This is a multicerter, randomized, double-blind, placebo-controlled trial to assess the efficacy of Jin-shui Huan-xian granule in reducinig the acute exacerbations, improving exercise capacity, and delaying the disease progression for IPF. After a 2-week wash-out period, 312 patients will be randomly assigned into treatment or control group for 52-week treatment. The primary outcomes are frequencies of acute exacerbation, 6-minute walking test, and percentage of patients with progression-free survival. The secondary outcomes include pulmonary function, all-cause mortality, clinical symptoms, dyspnea score, and quality of life. Safety will also be evaluated.
Participants in this group will participate in a 6 day meditation retreat at the La Costa Resort and Spa in Carlsbad, CA. They will be self-selected to participate in the retreat or are novice meditators randomized into this retreat.
In the control arm, participants will receive standard care and a reduced capability version of the RE-BUILD app to be used for data-capture only. They will also receive phone/Zoom calls at the same frequency during the 12-week intervention period, but no health advice will be given. After 26 weeks, participants in this group will receive access to the fully functional RE-BUILD app.
This invention relates to a base powder for preparing functional beverages, soft drinks or as an additive for food products, prepared with the paddle cactus Opuntia joconostle F.A.C. Weber and/or Opuntia matudae Scheinvar, or any other, equivalent fruit. It is prepared with the dried juice and pulp of the fruit and, optionally, with the addition of fruit fibre and/or sweetener or sugar substitute. The juice extract from said paddle cactus or any other, equivalent fruit is obtained by slowly heating a cooking vessel containing the ground fruit without exceeding 700°C, or a receptacle with fruit, using the bain marie method, without exceeding 700°C. The juice is stabilized, dried, mixed with fibre and optionally with sugar substitutes, and finally homogenized. The object of this invention is to provide a base powder of natural origin in a food presentation that is totally different from paddle cactus presentations currently on the market. A further object is to utilize the therapeutic properties of the fruit as coadjuvant in controlling weight and diabetes and in promoting health in general. It is 100% rehydratable in water, easy to transport and has a shelf life in excess of one year.
The invention discloses a D-carvone which has the function of resisting carbapenem bacteria and can enhance the treatment effect of carbapenem antibiotics by reversing the drug resistance of the carbapenem bacteria. The inventor performs bacteriostasis research on D-carvone, and adopts combined drug sensitization experiments to prove that the D-carvone has synergistic effect on carbapenem antibiotics meropenem. In addition, in vitro drug resistance reversal experiments show that the D-carvone can reverse the drug resistance of drug resistant bacteria to meropenem. In vivo experiments, D-carvone can enhance the therapeutic effect of meropenem. In conclusion, the D-carvone can be used as a carbapenem-resistant bacterial drug and can also be used as a carbapenem antibiotic synergist for reversing bacterial drug resistance and improving in-vivo therapeutic action. Therefore, the invention solves the prevention and control problems of carbapenem drug-resistant bacteria, can overcome the problems of poor curative effect and large dosage caused by drug resistance in clinical treatment, greatly reduces the drug cost and reduces the generation and spread of bacteria.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to methods of use of antifibrin antibody for inhibition of thrombus formation in vitro and to pharmaceutical composition and set containing pharmaceutical composition for use in these methods. Method involves the use of monoclonal MN-1 antibody produced by hybridoma AFSS 9739. Invention ensures to inhibit thrombus formation in the point of blood vessel damage. EFFECT: enhanced effectiveness of agent. 24 cl, 2 dwg
Beekeepers with \> approximately 10 stings/year who have been beekeeping for \>3 years. No history of anaphylaxis.
The invention discloses a colorectal polyps biological inhibitor. Its raw material formula contains, by weight, phenacetin, poplar bark, Saw palmetto fruit, Cryptolepis sanguinolenta (Lindl.)Schlecter, Armillariella tabescensand woad. When applied to a patient with colorectal polyps, the colorectal polyps plant inhibitor can effectively inhibit growth of colorectal polyps and further make colorectal polyps atrophy and disappear. When applied to high-risk groups with colorectal polyps at low doses, the colorectal polyps plant inhibitor can effectively reduce morbidity of colorectal polyps for an experimental group. Meanwhile, the inhibitor provided by the invention also can effectively inhibit relapse of colorectal polyps after recovery and prevent conversion of colorectal polyps to tumor. Effectiveness of a placebo is excluded out of the above effects. Moreover, obvious toxic or side effect never appears. The inhibitor is of great significance for improving living quality of patients, prolonging lifetime of patients and reducing morbidity and mortality of colorectal cancer.
Hyperbilirubinemia can occur with capecitabine. In the 875 patients with metastatic breast or colorectal cancer who received capecitabine as a single agent, grade 3 hyperbilirubinemia occurred in 15% of patients and grade 4 hyperbilirubinemia occurred in 3.9%. Of the 566 patients who had hepatic metastases at baseline and the 309 patients without hepatic metastases at baseline, grade 3 or 4 hyperbilirubinemia occurred in 23% and 12%, respectively. Of these 167 patients with grade 3 or 4 hyperbilirubinemia, 19% had postbaseline increased alkaline phosphatase and 28% had postbaseline increased transaminases at any time (not necessarily concurrent). The majority of these patients with increased transaminases or alkaline phosphatase had liver metastases at baseline. In addition, 58% and 35% of the 167 patients with grade 3 or 4 hyperbilirubinemia had pre- and postbaseline increased alkaline phosphatase or transaminases (grades 1 to 4), respectively. Only 8% (n=13) and 3% (n=5) had grade 3 or 4 increased alkaline phosphatase or transaminases.

In the 596 patients who received capecitabine for metastatic colorectal cancer, the incidence of grade 3 or 4 hyperbilirubinemia was similar to that observed for the pooled population of patients with metastatic breast and colorectal cancer. The median time to onset for grade 3 or 4 hyperbilirubinemia was 64 days and median total bilirubin increased from 8 µm/L at baseline to 13 µm/L during treatment with capecitabine. Of the 136 patients with grade 3 or 4 hyperbilirubinemia, 49 patients had grade 3 or 4 hyperbilirubinemia as their last measured value, of which 46 had liver metastases at baseline.

In the 251 patients with metastatic breast cancer who received capecitabine with docetaxel, grade 3 hyperbilirubinemia occurred in 7% and grade 4 hyperbilirubinemia occurred in 2%.

Withhold capecitabine and then resume at a same or reduced dose, or permanently discontinue, based on occurrence [see Dosage and Administration ( 2.5)] . Patients with Grade 3-4 hyperbilirubinemia may resume treatment once the event is Grade 2 or less than three times the upper limit of normal, using the percent of current dose as shown in Table 1 [see Dosage and Administration ( 2.5)] .
The invention relates to a cooling and health-care beer capable of balancing body-building, compressively preventing cold and diabetes mellitus, and beautifying, comprising traditional beer. The invention is characterized in that medicine parts are added into 100-part traditional beer according to the percentage by weight, and the medicine is composed of Chinese yam, mulberry leaves, kudzu roots, matrimony vines, coix seeds and lily bulbs. According to the disease treating theory of improving the general condition and eliminating the causative agents and separately leaving three types of diabetes of traditional medicine, the invention correspondingly resolves the theory of the separately leaving three types of diabetes of the drinking of human body and eliminates the harm of existing beet to human body. By being accurately dispensed in the course of the production of beer, the medicament can bring biomass active components to the beer. The medicament components are absorbed through drinking, and then the body-building is balanced, and the cold and diabetes mellitus are comprehensively prevented. The invention is adaptable for all people, and anyone who is ill or not can drink. The invention can be illness-proof and disease-curing, and thereby the invention is pure cooling and health-care beer with high nutrition for recuperation.
The invention discloses a cough relieving, dryness clearing and lung nourishing pill, which is prepared from the following components in part by weight: the traditional Chinese medicine composition is prepared from 12 traditional Chinese medicines including radix ophiopogonis, radix polygonati officinalis, folium mori, almonds, liquorice, perilla fruits, loquat leaves, schisandra chinensis, adenophora tetraphylla, bamboo shavings, pear peels, hyacinth beans and the like. 1. Has no influence or little influence on normal physiological functions and no toxic or side effect. 2. The effect is nonspecific and broad-spectrum. 3. Has effects in regulating lung yin deficiency, phlegm with blood, dry cough without phlegm, nourishing yin, moistening lung, dispelling pathogenic wind, nourishing yin, dispersing lung qi, relieving cough, invigorating stomach, and protecting lung fluid. 4. Can effectively improve symptoms and signs of a patient with lung yin deficiency, nourish yin, moisten lung, eliminate pathogenic factors, strengthen body resistance and treat lung yin.
PCT No. PCT/FR90/00484 Sec. 371 Date Feb. 28, 1992 Sec. 102(e) Date Feb. 28, 1992 PCT Filed Jun. 29, 1990 PCT Pub. No. WO91/00106 PCT Pub. Date Jan. 10, 1991.The present invention relates to injectable multi-phase solutions of W/O/W type, usable as vaccines or as vehicles of active substances in human and veterinary medicine, which are pharmaceutically acceptable in each one of their constituents, stable for at least 12 months in storage at 4 DEG  C., of viscosity less than 300 mPas and comprise at least the following constituents: an oily adjuvant composed of: a water-immiscible oily phase representing between 20 and 70% of the formula, an emulsifying system selected so that the inversion point of the resulting emulsion ranges between 25 DEG  and 45 DEG  and represents between 2 and 10% of the formula, an aqueous phase containing the antigens or the active substances and representing between 20 and 78% of the formula and obtained in a single mixing operation.
Hydrochlorothiazide, a sulfonamide, can cause acute transient myopia and acute angle-closure glaucoma (idiosyncratic reactions). Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of hydrochlorothiazide initiation. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. 

Untreated acute angle-closure glaucoma can lead to permanent vision loss. Given that LOPRESSOR HCT contains hydrochlorothiazide, if these symptoms occur, discontinue LOPRESSOR HCT. Consider prompt medical or surgical treatment if the intraocular pressure remains uncontrolled.
The subject matter disclosed herein provides methods for presenting glucose level data. Glucose data for a patient may be received. A current glucose level and a rate of change of the current glucose level may be determined based on the received glucose data. A first interface may be displayed on a screen of a device. The first interface may include a unitary icon. The unitary icon may display the current glucose level and a visualization of the rate of change. Related apparatus, systems, techniques, and articles are also described. <000 Con fn: L 0 WnU 0Ow 0 0 = D 0 0 > _U ZwU C - 0 .C LUJ w C
This study examined the long-term effects of a lifestyle modification program delivered at German Bundesliga football clubs. Weekly 90-minute group sessions over 12 weeks combined health education and physical activity and were delivered by coaches affiliated with the football clubs. A total of 371 men (mean age 49.7 years [SD = 7.6]) attended 41 classes at 19 clubs in 2017 and 2018 and participated in the long-term follow-up. Primary outcome was weight-loss at follow-up with a mean observation period of 20.4 months after baseline. Measures were taken partly by research staff and partly by participants themselves. At baseline, the men had a mean weight of 111.3 kg (SD = 16.9). Three months after baseline (posttest), the men had lost a mean of 6.3 kg (95% CI: 5.7-6.9). From posttest to follow-up, growth curve model showed men lost an average of 0.8 kg (95% CI: 0.2-1.4). Weight regain from posttest to follow-up of at least 3% was observed in 75 participants (20.2%) and was associated with less improvement in vegetable consumption in an adjusted logistic regression model. The data suggest that participation in a male-only lifestyle modification program offered by German football clubs may lead to sustained weight loss, but lack of a randomized control group and drop-outs prevent generalization of the results.
OBJECTIVES: Spatial cognition is a perceptual-motor function that pertains to the comprehension and processing of two-dimensional and three-dimensional space. The impairment of any sensory system can have adverse effects on cognitive functioning. The objective of this study is to examine spatial cognition in adults with hearing impairments.
METHODS: There were a total of 61 individuals in this study: thirty-six with hearing loss and 25 with normal hearing. The Spatial Orientation Test (SOT), the Mental Rotation test (MR), and the Money's Road Map Test (RMT) were administered to assess participants' spatial learning-orientation, mental imagery-rotation, and spatial navigation abilities. A high number of errors in RMT, high angle difference in SOT and a low score in MR suggest poor spatial abilities.
RESULTS: Participants with hearing loss had a greater number of RMT errors and SOT angle difference, but lower MR scores than those with normal hearing (P < .001). Hearing impairment negatively impacted all 3 spatial cognitive assessments. Hearing loss was associated with a 6.9 increase in the number of RMT errors (95% Confidence Interval (CI): 4.8, 9), a 23.6 increase in the SOT angle difference (95% CI: 16, 31.2), and an 8.5 decrease in the MR score (95% CI: -10.8, -6.2).
CONCLUSIONS: The study found that individuals with hearing loss exhibited lower performance in various cognitive tasks related to spatial orientation, navigation, spatial learning, mental imagery, and rotation abilities when compared to an age and sex matched control group. In future study, it is imperative to place greater emphasis on hearing loss as a potential detrimental factor in the prediction of spatial cognition impairment.
The stroke-Specific Quality of Life Scale is regarded as one of the most extensive and more commonly utilized patient-centred and self-reported measure of outcomes in the stroke population. The SS-QoL scale is a health-related outcome measure that comprises 49 items in 12 areas of vision, mobility, thinking, social roles, self-care, language, personality, family roles, work/productivity, upper limb function, mood and energy. It covers a more extensive inclusion of capacities ordinarily influenced by stroke.

The Stroke Specific Quality of Life questionnaire, originally developed in English, has been translated into many languages to assess for its validity and reliability ever since, but not any of the Pakistani native versions are made or tested. Previous studies have shown that the translation of the scale would end up giving a standard measure to be utilized in clinical practices and research studies while sanctioning clinicians and specialists to share information and have an insight into patient's health-related concerns post-stroke. Thus, it is imperative to translate this questionnaire into psychometrically sound versions of indigenous Pakistani languages such as Urdu, Punjabi, Sindhi, Balochi and Pashto. This may promote an easy understanding of the local population in Pakistan where the languages are spoken and will provide a valid measure of stroke-specific health outcomes to be clinically utilized by practitioners and researchers across the country.
BACKGROUND: The neurological prognosis of asphyxia is poor and the effect of advanced airway management (AAM) in the prehospital setting remains unclear. This study aimed to evaluate the association between AAM with adrenaline injection and prognosis in adult patients with asystole asphyxia out-of-hospital cardiac arrest (OHCA).
METHODS: This study assessed all-Japan Utstein cohort registry data between January 1, 2013 and December 31, 2019. We used propensity score matching analyses before logistic regression analysis to evaluate the effect of AAM on favorable neurological outcome.
RESULTS: There were 879,057 OHCA cases, including 70,299 cases of asphyxia OHCAs. We extracted the data of 13,642 cases provided with adrenaline injection by emergency medical service. We divided 7,945 asphyxia OHCA cases in asystole into 5,592 and 2,353 with and without AAM, respectively. After 1:1 propensity score matching, 2,338 asphyxia OHCA cases with AAM were matched with 2,338 cases without AAM. Favorable neurological outcome was not significantly different between the AAM and no AAM groups (adjusted odds ratio [OR] 1.1; 95% confidence interval [CI], 0.5-2.5). However, the return of spontaneous circulation (ROSC) (adjusted OR 1.7; 95% CI, 1.5-1.9) and 1-month survival (adjusted OR 1.5; 95% CI, 1.1-1.9) were improved in the AAM group.
CONCLUSION: AAM with adrenaline injection for patients with asphyxia OHCA in asystole was associated with improved ROSC and 1-month survival rate but showed no differences in neurologically favorable outcome. Further prospective studies may comprehensively evaluate the effect of AAM for patients with asphyxia.
Coronaviruses belong to the genus of coronavirus of the family coronaviruses. The viruses of the coronavirus genus are positive-sense single-stranded RNA viruses with envelopes, which are approximately 80-160 nm in diameter. Their genetic material is the largest among all RNA viruses and can infect both humans and animals. Coronaviruses can cause respiratory, intestinal, hepatic, and nervous system diseases of different severities. A total of 7 coronaviruses have been found, in which HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1 mainly lead to mild and self-limiting upper respiratory tract infections in infected humans, such as common cold; two new types of β-coronaviruses have emerged in the past 12 years, namely severe acute respiratory syndrome (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV), and these two viruses can cause severe human diseases.

In the first human clinical trial conducted in the United States, single and multiple dosing of FB2001 in multiple dose groups were partially completed，and FB2001 demonstrated good safety and tolerability. The bridge study of FB2001 will be conducted in China to evaluated the safety and PK of FB2001 in healthy Chinese population. This study is a randomized, double-blinded, placebo-controlled, ascending dose to evaluate the pharmacokinetics, safety and tolerability of FB2001 for injection afer a single and multiple dose administrations in healthy subjects. A total of 40 healthy subjects are planned to be enrolled. Each group will include 8 subjects.
Whether given orally or by continuous or intermittent intravenous infusion, milrinone lactate has not been shown to be safe or effective in the longer (greater than 48 hours) treatment of patients with heart failure. In a multicenter trial of 1088 patients with Class III and IV heart failure, long-term oral treatment with milrinone lactate was associated with no improvement in symptoms and an increased risk of hospitalization and death. In this study, patients with Class IV symptoms appeared to be at particular risk of life-threatening cardiovascular reactions. There is no evidence that milrinone lactate given by long-term continuous or intermittent infusion does not carry a similar risk.

The use of milrinone lactate both intravenously and orally has been associated with increased frequency of ventricular arrhythmias, including nonsustained ventricular tachycardia. Long-term oral use has been associated with an increased risk of sudden death. Hence, patients receiving milrinone lactate should be observed closely with the use of continuous electrocardiographic monitoring to allow the prompt detection and management of ventricular arrhythmias.